- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Silver47 Exploration
Syntheia
Black Swan Graphene
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Bod Australia Expands Product Line with Import Licence
With three products in its line, Bod now has access to an additional 32 percent of the medical cannabis prescription market in Australia.
Medical cannabis company Bod Australia (ASX:BDA) has increased its product line with the receipt of a new import permit.
On Tuesday (February 11), the cannabis company told investors that it has received approval from the New South Wales Department of Health and Office of Drug Control to import two new cannabidiol (CBD) isolate products with 2.5 percent and 10 percent strengths.
With the new offerings, which will be sold under Bod’s MediCabilis brand, the company will now have three products in the line. According to the firm, that gives it access to an additional 32 percent of the medicinal cannabis prescription market in Australia.
Shares of Bod were up 3.7 percent from market close on Tuesday to the end of the trading session on Wednesday (February 12), ending the trading day at AU$0.28.
CEO Jo Patterson said in a statement that the new products are a result of the company’s considerable work in research and development.
“Bod is one of the only companies to have completed a Phase I clinical trial using a finished dose form and cannabis extract and this gives prescribers and patients tremendous confidence in our product,” the executive said.
The CBD isolate is derived from Bod’s exclusive full plant extract, which is also used in the original MediCabilis 5 percent CBD offering. The first of the products in the MediCabilis line has been prescribed over 2,000 times over the past 12 months, Bod said.
Patterson added that the products’ categorization as Schedule 4 substances means lower barriers for restrictions and use, further allowing the company to maximize its market penetration.
According to the Therapeutic Goods Association, the Schedule 4 category is designated for prescription-only medicines or prescription animal remedies.
Along with the first product in the MediCabilis line, the two new medicines will be available through the Special Access Scheme Category B pathway and through approved prescribers.
With the expanded line, Bod is confident that prescription volumes will rise in the coming months as patients and physicians seek out alternative treatments for pain, nausea and inflammatory conditions.
Apart from its operations within Australia, Bod’s international initiatives in its medical marijuana, hemp and CBD division are progressing as well, Patterson said.
In its report for the second fiscal quarter of 2020, Bod highlights the launch of its first CBD products to market in the UK through a partnership with Happiness Group (HKEX:1112).
Sales for Bod’s most recent quarter were at AU$536,000, bringing the total amount of sales in the first half of its fiscal 2020 year to AU$1.04 million. The firm noted that it had about AU$8.1 million in cash by the end of the quarter.
Don’t forget to follow us @INN_Australia for real-time news updates!
Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.
2024 Life Science Outlook Report
Get the trends and expert predictions you need to stay ahead of the markets.
Download your outlook report today.
Learn About Exciting Investing Opportunities in the Life Science Sector
Your Newsletter Preferences
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Danielle is a staff writer with INN. She graduated from the Master of Journalism program at Carleton University after completing her undergraduate degree in Media Studies at the University of Guelph-Humber. She's written for the Globe and Mail, the Canadian Press, the National Post and the Brampton Guardian. She spends her time covering the cannabis market for INN.
Learn about our editorial policies.